Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 30/5/2020
SIETES contiene 93014 citas

 
 
 1 a 5 de 5 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Pasternak B, Wintzell V, Melbye M, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Svanström H, Ueda P. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BMJ 2020;369:29 de abril. [Ref.ID 103626]
2. Cita con resumen
Pasternak B, Ueda P, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveern K, Jonasson C, Wintzell V, Melbye M, Svanström H. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ 2019;366:29 de agosto. [Ref.ID 103243]
3.Enlace a cita original Cita con resumen
Ueda P, Svanström H, Melbye M, Eliasson B, Svensson A-M, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 2018;363:14 de noviembre. [Ref.ID 102869]
4. Cita con resumen
Rawshani A, Svensson A-M, Zethelius B, Eliasson B, Rosengren A, Gudbjömsdottir S. Association between socioeconomic status and mortality, cardiovascular disease, and cancer in patients with type 2 diabetes. JAMA Intern Med 2016;176:1146-54. [Ref.ID 100702]
5. Cita con resumen
Ekström N, Schiöler L, SVensson AM, Eeg-Olofsson E, Jonasson JM, Zethelius B, Cederholm J, Eliasson B, Gudbjörnsdottir S. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open 2012:11 de diciembre. [Ref.ID 93276]
Seleccionar todas
 
 1 a 5 de 5